So Open Orphan are just a Covid play right? WRONG
“…We have a hugely diversified Business model. We are making money, we are profitable, we are growing and we can not say that about some of our friends…”
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
So, with the pfizer news out this week, how does that leave Cathal Friel and his Open Orphan Team feeling? People seemed almost surprised that a possible vaccine has been found, some almost upset. This is certainly not the the view here in this interview with Executive Chairman Cathal Friel.
As Cathal explains in this catch up with Doc Holiday, around 90% of Open Orphan’s business is NON covid which may explain why the share price is more or less around the same price as pre “Vaccine Monday” unlike many other companies, which is a great credit to Cathal and shows that the company really is not just a one-trick-pony outfit.
“We are making money, we are profitable and we are growing and we can not say that about some of our friends” says Cathal. “We have a huge diversified business model” he says whilst also adding “We are in a decade of testing and development for vaccines. Next Summer, you will be taking your flu jab AND your Covid jab. To avoid another pandemic, we are entering a decade of exponential vaccine development and #ORPH has a massive pipeline of orders and prospects to test other vaccines including flu, RSV, malaria etc.” The future then, sounds very bright indeed for the company.
Listen below to Doc Holiday catch up with Cathal Friel and expand on the above a little more…
Below, Open Orphan PLC’s Cathal Friel presents at the Proactive One2One Virtual October Conference…
